53Biologics, a CDMO specializing in biologics production and cGMP manufacturing, opened a new GMP production line for microbial-based therapeutics. The new production line boasts a 2000L reactor.

The new addition to 53Biologics’s manufacturing facility allow them to meet the growing demand for microbial-based products and serve more clients across the globe. In addition to the 2000L reactor, the new GMP production line is equipped with a range of single-use downstream equipment, including chromatography systems, filtration units, and purification systems. The advanced technologies allow the company to produce high-quality, pure biologics products with a high yield and efficiency.

“We are thrilled to add this new GMP manufacturing line to our existing capabilities for biologics production,” said Pablo Gutierrez, CEO of 53Biologics. “This investment not only expands our capacity to 2000L but also enhances our ability to deliver high-quality services to our clients. The new plant enables us to scale-up production for larger batches, which can result in cost savings for our clients. It also enables us to better meet the growing demand for microbial-based biotherapeutics, which is increasingly becoming the focus of the pharmaceutical industry.”

According to the company, the installation of the new fermenter marks another milestone in 53Biologics’s ongoing efforts to expand its service offerings and meet the evolving needs of the biologics industry. With this new addition, 53Biologics is well-positioned to serve a wide range of clients, including those in the pharmaceutical, biotech and academic sectors.

“We are excited about the new opportunities this new plant brings to our company and our clients,” said Francisco Reyes, business development manager of 53Biologics. “We remain committed to delivering superior quality services to our clients, and this new 2000L fermenter will help us achieve that goal.”